Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 19/20 | 0.81 |
| ▸ | PTK2B | Q14289 | 10/20 | 0.81 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | PLK4 | O00444 | 1/20 | 0.81 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.81 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.81 |
| ▸ | JAK2 | O60674 | 1/20 | 0.81 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.81 |
| ▸ | STK16 | O75716 | 1/20 | 0.81 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.81 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.81 |
| ▸ | PAK4 | O96013 | 1/20 | 0.81 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.81 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.81 |
| ▸ | PRKCG | P05129 | 1/20 | 0.81 |
| ▸ | INSR | P06213 | 1/20 | 0.81 |
| ▸ | LCK | P06239 | 1/20 | 0.81 |
| ▸ | FYN | P06241 | 1/20 | 0.81 |
| ▸ | CDK1 | P06493 | 1/20 | 0.81 |
| ▸ | LYN | P07948 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5185891 | 0.94 | PTK2 (0.72) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5500420 | 0.92 | PTK2 (0.76) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5500570 | 0.92 | PTK2 (0.76) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5495668 | 0.90 | PTK2 (0.76) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5500856 | 0.90 | PTK2 (0.75) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5494328 | 0.90 | PTK2 (0.81) | PTK2PTK2BAURKAPLK4PDPK1 | |
| Pf-00562271 SCHEMBL29637167 | 0.90 | PTK2 (1.00) | PTK2PTK2BAURKAPLK4PDPK1 | |
| Pf-00562271 SCHEMBL29381854 | 0.90 | PTK2 (1.00) | PTK2PTK2BAURKAPLK4PDPK1 | |
| Pf-00562271 SCHEMBL1206959 | 0.90 | PTK2 (1.00) | PTK2PTK2BAURKAPLK4PDPK1 | |
| SCHEMBL5494449 | 0.89 | PTK2B (0.75) | PTK2PTK2BAURKAPLK4PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751143-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-02-14 | — | — | EP | claimed |
| US-7109337-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2006-09-19 | — | — | US | claimed |
| US-20060205945-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2006-09-14 | — | — | US | claimed |
| WO-2005111023-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050256145-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| US-20180177788-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | RGCM SA LLC, AS PURCHASER AGENT | 2018-06-28 | — | — | US | disclosed |
| EP-1751143-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7109337-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060205945-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| WO-2005111023-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256145-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205945-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2 3522/4885PTK2B 2693/4885AURKA 651/4885 |
| US-20050256145-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2 3522/4885PTK2B 2693/4885AURKA 651/4885 |
| US-20180177788-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | PTK2, CD274, PDCD1LG2 | PTK2 1/4885PTK2B 39/4885AURKA 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.